Community-acquired pneumonia in adults: who is at risk?
Official title: Epidemiological Study on Community Acquired Pneumonia
Run by Capnetz Stiftung · NCT02139163 · Data updated 2026-11-12
This project collects clinical data and biological samples from adults with community-acquired pneumonia to see which risk factors, causes, and outcomes are linked to the illness.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Capnetz Stiftung Academic / other |
| Locations | 1 site (Hanover) |
| Status | Recruiting |
| Started | October 2002 |
| Main results expected | December 2027 |
| Study ends | June 2028 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT02139163 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a new community-acquired pneumonia confirmed by chest X-ray who have cough, purulent sputum, abnormal lung auscultation (crackles), or fever and who can consent to follow-up and sample collection.
✕Probably not a fit
People under 18, patients with recently diagnosed active pulmonary tuberculosis, those hospitalized more than 48 hours before the pneumonia diagnosis, or anyone unwilling to provide consent or biological samples are unlikely to receive benefit from joining.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The CAPNETZ project is a prospective, multicenter observational cohort enrolling adults with radiographically confirmed community-acquired pneumonia from hospitals and outpatient clinics. At enrollment it records medical history, medications, physical exam findings, routine imaging, and collects blood, urine, and respiratory specimens for microbiology and chemistry. Participants have in-person follow-ups at days 3 and 7 and telephone follow-ups at 28 and 180 days while treating physicians provide usual care and no experimental interventions are applied. The study aims to map prevalence, risk factors, pathogen patterns, and how CAP interacts with comorbidities including immunosuppression and HIV.
Why it matters
Potential benefit: If successful, findings could help doctors identify high-risk patients and tailor diagnosis and treatment to reduce complications and deaths from CAP.
How similar studies have gone: Large observational cohorts including CAPNETZ and other epidemiological programs have previously identified common pathogens and risk factors for CAP, so this cohort design is well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 18 * infiltrate on chest X-ray * further Inclusion criteria (at least one must apply): cough or purulent sputum or pathologic lung auscultation (crackles) or fever Exclusion Criteria: * Hospitalization lasting longer than 48 hours prior to the diagnosis of the current pneumonia * Newly diagnosed, active pulmonary tuberculosis within the last 2 months
Where it's running
-
Medical School Hannover
Hanover, Germany Recruiting
Study contacts
- Study coordinator: Frank Eberhardt
- Email: office@capnetz.de
- Phone: +49-511-532-5927
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How frailty affects outcomes in older people with pneumonia in the ER
This study will test whether a quick bedside frailty score (the Clinical Frailty Scale) can help predict short-term death and serious complications in people aged 65 and older who come to the emergency department with pneumonia.
-
Fever clinic tracking of acute respiratory infections
This project follows adults who come to a fever clinic with respiratory infections to see how their symptoms, test results, and outcomes change over time.
-
Azithromycin versus doxycycline as atypical coverage for adults hospitalized with community-acquired pneumonia on a beta-lactam
This trial will test whether adding azithromycin or doxycycline to a beta-lactam works better and is safer for adults hospitalized with community-acquired pneumonia.
-
Noninvasive breathing support for severe community-acquired pneumonia
This trial tests whether high-velocity nasal insufflation (HVNI) or standard noninvasive ventilation (NIV) better helps adults with community-acquired pneumonia and low oxygen levels avoid intubation or death within 48 hours.
-
Antibiotic strategies for young children with pneumonia in outpatient care
This trial will see if a 'watch-and-wait' Safety Net Antibiotic Prescribing (SNAP) approach can safely reduce antibiotic use compared with immediate antibiotics in children aged 12 months to under 6 years with mild community-acquired pneumonia.
-
Awake prone positioning for adults with community-acquired pneumonia on high-flow nasal oxygen.
This trial will test whether asking adults with community-acquired pneumonia who are on high-flow nasal oxygen to lie on their stomach while awake can reduce the need for a breathing tube.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.